RAMB - Fevereiro 2017

13 / 110

Treatment of benign prostatic hyperplasia
Rev Assoc Med B ras 2017; 63(2):95-99 99
24. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A
systematic review and meta-analysis on the use of phosphodiesterase 5
inhibitors alone or in combination with α -blockers for lower urinary
tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;
61(5):994-1003.
25. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG,
et al. Tadalafil for the treatment of lower urinary tract symptoms secondary
to benign prostatic hyperplasia: pathophysiology and mechanism(s) of
action. Neurourol Urodyn. 2011; 30(3):292-301.
26. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka
AM, et al. Effects of once-daily tadalafil on erectile function in men with
erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
Eur Urol. 2009; 56(4):727-35.
27. Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, et al. Efficacy and
safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive
of benign prostatic hyperplasia: subgroup analyses of pooled data from 4
multinational, randomized, placebo-controlled clinical studies. Urology.
2013; 82(3):667-73.
28. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5
inhibitors used for the treatment of erectile dysfunction or pulmonary
hypertension. Circulation. 2010; 122(1):88-95.
29. Yan H, Zong H, Cui Y, Li N, Zhang Y. The efficacy of PDE5 inhibitors alone
or in combination with alpha-blockers for the treatment of erectile dysfunction
and lower urinary tract symptoms due to benign prostatic hyperplasia: a
systematic review and meta-analysis. J Sex Med. 2014; 11(6):1539-45.
30. Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu
S, et al. Efficacy and safety of the coadministration of tadalafil once daily
with finasteride for 6 months in men with lower urinary tract symptoms
and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol.
2014; 191(3):727-33.
31. Roehrborn CG, Casabé A, Glina S, Sorsaburu S, Henneges C, Viktrup L.
Treatment satisfaction and clinically meaningful symptom improvement
in men with lower urinary tract symptoms and prostatic enlargement
secondary to benign prostatic hyperplasia: secondary results from a 6-month,
randomized, double-blind study comparing finasteride plus tadalafil with
finasteride plus placebo. Int J Urol. 2015; 22(6):582-7.